BRAF and colorectal carcinoma: Further study on the mechanism found that simvastatin can inhibit the expression of murine sarcomatoid oncogene homologous B1 (BRAF), phosphorylated extracellular regulatory protein kinase 1/2 (p-ERK 1/2), and other proteins, thereby inhibiting the MAPKs pathway activity and reducing the resistance of CRC to cetuximab [33].